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Abstract ThelysosomalenzymesN-acetylglucosaminidase (N-ACGA) and b-galactosidase (b-gal) areinvolvedin cel-
lular collagen metabolism and may, therefore, be markers of fibrosis in idiopathic interstitial pneumonias, such as idio-
pathic pulmonary fibrosis (IPF). N-ACGA and b-gal were analyzed in the bronchoalveolar lavage fluid (BALF) of
patients with the histologic pattern of usual interstitial pneumonia (UIP, n¼10) and controls (n=9).Cellular distribution in
BALFaswell as the concentrationof TGF-b awell-knownmediatorof fibroblastmatrixdepositionwere correlatedtothe
enzyme activities in both groups of patients.We found that both,N-ACGA (UIP: 25.2 nmol/l s73.4; controls: 7.3 nmol/
l s71.3) and b-gal (UIP: 4.7 nmol/l s70.5; controls: 2.4 nmol/l s70.3) were elevated significantly in BALFof patientswith
IPF compared to that of control patients (Po0.003). This increase was paralleled by an increase in neutrophils (IPF:
17.9%721.8; controls: 5.4%76.3; P¼0.03) and eosinophils (IPF: 2.0%71.5; controls: 0.2%70.45; P¼0.002) in BALF fluid.
In addition,N-ACGA activity correlated closely with lung function (FVC,TLC, and DLCO), transforming growth factor-
beta (TGF-b) in BALF (r¼0.77, P¼0.008) and activated lymphocytes (r¼0.66, P¼0.0021).Our findings suggest that mea-
surementof lysosomal enzymes such asN-ACGAmayrepresent a useful indicator of fibrotic activity in IPF.
r 2002 Elsevier Science Ltd.Allrights reserved.
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Idiopathic pulmonary ¢brosis (IPF) is a relatively rare,
progressive pulmonary disease. According to a recent
classi¢cation (1), IPF is the disease associated with the
histological pattern termed as usual interstitial pneumo-
nia (UIP). The prognosis of this disease is bad as 5-year
mortality has been reported to be 50% but studies invol-
vingmerely UIP-classi¢edpatients remain a minority.
The assumption is made that in£ammation leads to
lung injury and ¢brosis (2). In£ammatory cells ¢rst accu-
mulate in the alveolar and in the interstitial compart-
ment. As this process is perpetuated a reparative
mechanism involving increased production and activa-
tion of transforming growth factor-beta (TGF-b) ensues.
This process, which is pro-¢brotic more than pro-in-
£ammatory involves a distinct set of activated genes (3).Received 5 February 2002, accepted in revised form 27 February 2002.
Correspondence should be addressed to:Dr.Christian Gessner,
Department of Internal Medicine, Pulmonary Unit, Johannisallee 32,
04103 Leipzig,Germany.Fax: +49-341-97-12609;
E-mail: gesc@medizin.uni-leipzig.deAccordingly, recent therapeutic e¡orts have been aimed
to target the ¢brotic process rather than being anti-in-
£ammatory or immunosuppressant (4).
It is still unclear how tomonitor the ¢brotic response
in IPF and other IPs.TGF-b has been found to be elevated
in IPF patients (5) and may represent a key pro-¢brotic
factor. Type III collagen aminopropeptide has been used
as another marker in silicosis-associated pulmonary ¢-
brosis, in idiopathic systemic scleroderma and in IPF (6^
8).No surrogate parameter, however, will be able to bet-
ter demonstrate ¢brotic activity than the activity of en-
zymes actually involved in the matrix synthesis and
breakdown. One of them is the enzyme collagenase,
which catalyzes the initial step in collagen degradation.
Decreased collagenase activity has been shown in the
skin of patients with progressive systematic sclerosis (9).
Several other enzymes involved in collagen synthesis
have been associated with ¢brotic activity (10). One of
them, the lysosomal enzyme beta-galactosidase (b-gal)
cleaves hydroxyllysine-galactose from collagen’s pro-a
chains during collagen synthesis (6,11,12). A second lysoso-
mal enzyme is N-acetylglucosaminidase (N-ACGA)
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N-acetylglucosamine from the C-terminal propeptide of
pro-collagen (13). It has been shown that activated ¢bro-
blasts are the main source of elevated N-ACGA and b-
gal activity in progressive systemic sclerosis (PSS) (10).
N-ACGA and b-gal activity has been investigated pre-
viously in several ¢brosing connective tissue diseases,
such as PSS, systemic lupus erythematodes, rheumatoid
arthritis, dermatomyositis and Raynaud’s disease (14). All
of these diseases are characterized by increased lysoso-
mal enzyme activity in serum. In addition,N-ACGA has
been shown to be amaker formonitoring activityof liver
cirrhosis (15,16).
The present study investigates the use of the lysoso-
mal enzymes N-ACGA and b-gal as markers of ¢brotic
activity in IPF.
MATERIALANDMETHODS
Study population
Ten consecutive patients with IPF and nine control pa-
tients were included. Patients with IPF have been histo-
pathologically diagnosed by surgical lung biopsy to have
UIP (17).Control patients had non-small cell lung cancer
(n=2), chronic obstructive pulmonary disease (n=5), and
asthma (n=2). None of the patients with IPF, but ¢ve of
the control patients were current smokers.The remain-
ing ¢ve controls had stopped smoking at least11months
prior to inclusion into the study. None of the patients
were suspected to have pneumonia. At the time of
bronchoalveolar lavage (BAL) no patient received corti-
costeroids or other immunosuppressants.
Bronchoalveolar lavage
All subjects underwent ¢beroptic bronchoscopy and
BAL according to guidelines (18,19) as part of their diag-
nostic work-up. BAL was carried out in the rightmiddle
lobe and in the lingual lobe using ¢ve 20ml aliquots. In
the two patients with NSCLC, the tumor was located in
a lung lobe not identical to the one lavaged. Recovered
BAL £uidwas pooled, ¢ltered through gauze and centri-
fuged at 3000 g for 10min at 41C. Cell number was
counted in a hemocytometer (20). Cell viability was
determined by trypan blue staining (21). Di¡erential
cell counts were performed using cytospin specimens
following May^Grˇnwald Giemsa staining. Lymphocyte
subpopulations of BALF were analyzed by immuno£uor-
escence £ow cytometry. Cell surface antigens were
stained with £uorescein isothiocyanate (FITC) or phy-
coerythrin (PE)-conjugated murine monoclonal antibo-
dies (mAbs): anti-CD25-PE, anti-CD57-FITC (Beckman-
Coulter, Krefeld, Germany), anti-CD3-FITC, anti-CD4-
PE, anti-CD8-PE, anti-CD14-PE, anti-CD16-PE, anti-
CD19-PE, anti-CD45-FITC, anti-CD56-PE, anti-HLA-DR-PE (BD Biosciences, Heidelberg, Germany), anti-
CD71-PE (Dako, Hamburg, Germany), and anti-lgG1-
FITC/anti-lgG2a-PE (BDBiosciences). Samples were ana-
lyzed on a FACScans (BDBiosciences).
Pulmonary function testing
All individuals underwent a complete pulmonary func-
tion test. In this study, the relative individual forced vital
capacity (FVC), total lung capacity (TLC), forced expira-
tory volume (FEV1), and transfer factor (DLCO)were de-
termined.
Biochemical analysis of lysosomal enzymes
Activities of the lysosomal enzymes N-ACGA and b-gal
were measured in serum and BALF by luminescence-
spectrometry (Perkin^Elmar LS50; Perkin^Elmar Co.,
Beacons¢eld,U.S.A.).MeasurementofN-ACGAwasper-
formed by £uorescence-spectrometry as described by
O’Dowd et al. (22). For measurement of b-gal activity,
we modi¢ed the method described by Herrmann and
coworkers (14) doubling the sample volume.
Analysis of transforming growth factor-beta
(TGF-b)
A humanTGF-b immunoassay with a minimum detect-
able dose of 7 pg/mlwas used (R&D Systems, Minneapo-
lis,U.S.A.).
Statistical analysis
Statisticswere analyzedusing the SPSS softwarepackage
(SPSS Inc., Chicago, U.S.A.). For comparison of numeric
parameters of patient groups (IPF vs controls) the
Mann^WhitneyU test, for correlation of nonparametric
parameters Pearson’s w2-test was used. Data shown are
mean7SD.
RESULTS
Patient characteristics and BAL ¢ndings
No signi¢cant age di¡erence existed in the two groups of
patients (IPF: 48; controls: 56; P¼0.1). BALF recovery
was comparable in both groups (IPF: 44.8% 76.0;
controls: 47.8%78.7; P¼0.36), this was also true for the
total number of cells (IPF: 25.510679.8; controls:
20.4106717.4; P¼0.21). However, the number of cells/
ml of BALF was signi¢cantly increased in IPF patients
compared to controls (IPF: 31.5104712.9; controls:
17.8104710.8; P¼0.035).Cell viability was485% in all
samples analyzed.
FIG. 1. Enzyme activity in BALF:
N-ACGA (A) and b-gal (B) activities in BALF in IPF and control
patients (Po0.0001;Po0.003).
TABLE 1. Pulmonary functiontesting
Lung function
parameter
N-ACGA b-gal
FCV* r¼0.59 (P¼0.008) r¼0.44 (NS)
FEV1* r¼0.29 (NS) r¼0.02 (NS)
TLC* r¼0.67 (P¼0.002) r¼0.59 (P¼0.008)
DLCO* r¼0.64 (P¼0.003) r¼0.49 (P¼0.034)
*Percentpredicted.
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The percentage of macrophages was signi¢cantly de-
creased in the IPF group (IPF: 60.5%723.4; controls
86.9%76.6; Po0.0001). The total amount of macro-
phages, however, did not di¡er signi¢cantly between the
two groups (IPF: 14.8106 cells77.6; controls: 17.6106
cells714.7;P¼0.97).
Neutrophils (percentage) were increased to 17.9%
721.8 in IPF patients compared to controls (5.4%76.3;
P¼0.03).This di¡erence was also observed when the to-
tal number of neutrophils (IPF: 5.5106 cells 7.3; con-
trols: 0.9106 cells70.9;P=0.017) was analyzed.
Finally, we observed increased eosinophils in IPF pa-
tients both relatively (2.0%71.5; controls: 0.2%70.45;
P¼0.002), as well as absolutely (IPF: 0.81106
cells70.82; controls: 0.07106 cells70.15;P¼0.004).
No relative or absolute increase in lymphocytes was
observed in BALF of IPF patients (IPF: 18.7%722.1; con-
trols: 7.4%74.8; P¼0.21; absolute: IPF: 4.4106
cells75.4; controls:1.8106 cells72.1;P¼0.18).
A subgroup analysis of lymphocytes exhibited no dif-
ferences in B-lymphocytes (IPF: 1.2%70.6; controls:
2.2%73.0; P=0.84), T-lymphocytes (IPF: 95.3%73.5;
controls: 86.0%717.7; P¼0.24), natural killer cells (NK-
cells; IPF: 3.5%73.5; controls: 11.8%718.3; P¼0.24), or
CD4/CD8-ratio (IPF: 0.8170.57; controls: 1.1470.54;
P¼0.11). In contrast, patients with IPF had an increased
percentage of activated T-lymphocytes (CD3/HLA-DR;
IPF: 54%720.9, controls:18.6%720.7;P¼0.002).
Lysosomal enzymes in serumand BALF
Analysis of serum activity of the lysosomal enzymes N-
ACGA (IPF: 205.1nmol/l s737.0; controls: 204.3 nmol/l s
749.5; P=0.72) and b-gal (IPF: 15.9nmol/l s77.71; con-
trols: 18.3 nmol/l s78.55; P¼0.55) did not reveal signi¢-
cant di¡erences between IPF and control patients.
In contrast, the activities of the lysosomalN-ACGA in
BALF were increased in the IPF group (25.2nmol/
l s710.7) vs controls (7.3nmol/l s73.9;Po0.0001,Fig.1(A)).
Similar di¡erences in activity were observed for lysoso-
mal b-gal in BALF (IPF: 4.7 nmol/l s71.6; controls:
2.4nmol/l s70.9;Po0.003, Fig.1(B)).
Pulmonary function testing
Patients with IPF exhibited a signi¢cantly reduced FVC
(IPF: 63.7%76.0; controls: 82.6%714.1; Po0.006), TLC
(IPF: 67%76.3; controls: 105.1%710.8; Po0.0001), and
DLCO (IPF: 55.8%710.4; controls; 86.6%79.6).No di¡er-
ence in FEV1 was observed (IPF: 69.5%74.7; controls:
71.7%78.1;P¼0.4).
N-ACGA and b-gal activity correlated indirectly to
TLC and DLCO (Table1).Correlation of cellular pro¢lewith lysosomal
enzyme activity
BALdi¡erential cell countwas correlatedwith lysosomal
enzyme activity in BALF.ForN-ACGAwe observedane-
gative correlation with the percentage of macrophages
(r¼0.67,P¼0.002) and a positive correlationwith theper-
centage of neutrophils (r¼0.55, P¼0.016) but more so
FIG. 2. Correlation of activated T-lymphocytes and N-ACGA (A) (r¼0.67; P¼0.002) as well asTGF-b concentration in BALF (B)
(r¼0.74, P¼0.0001).
FIG. 3. Correlation of TGF-b concentration (BALF) and N-
ACGA (r=0.79, P=0.0001) in IPFcontrols.
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P¼0.002).This was also true when the absolute number
of cells in BALF was correlated (data not shown).
Although no correlation of N-ACGAwith lymphocytes
(either relative or absolute) was seen, the percentage of
activated lymphocytes was closely correlated to N-
ACGA activity (r¼0.66, P¼0.0021, Fig. 2(A)).
Lysosomal b-gal activity was negatively correlated to
thepercentage ofmacrophages (r¼0.68,P¼0.001, andpo-
sitively correlated to the percentage of eosinophils
(r¼0.5, P=0.033). As already shown for N-ACGA, b-gal
activity was correlated to the total number of neutro-
phils (r¼0.46, P¼0.04) as well as to the total number of
eosinophils (r¼0.59,P¼0.007).Thepercentage of lympho-
cytes, the total number of lymphocytes in BALF and in
discordance to N-ACGA the percentage of activated
lymphocytes did not correlate signi¢cantly with b-gal
activity.
TGF-b analysis
Total BALF TGF-b concentration was higher in the IPF
group (34.4 pg/ml714.9) than in the control group
(21.6pg/ml76.6) but did not quite reach signi¢cance:
P¼0.053. However, BALF TGF-b concentrations exhib-
ited a strong linear correlation with N-ACGA activity in
BALF (r¼0.79,P¼0.0001, Fig. 3). In contrast, no signi¢cant
correlation was found for BALF activity of b-gal and
TGF-b concentration.
Thepercentage of activated T-lymphocyteswas found
to be correlated to TGF-b concentrations (r¼0.74,
Po0.0001, Fig. 2(B)), as well as to N-ACGA activity (see
above).DISCUSSION
It has been demonstrated that pulmonary ¢brosis
is a heterogeneous group of diseases that can be
di¡erentiated by histology (17). This di¡erentiation is
very relevant to prognosis (23). IPF is one of the intersti-
tialpneumoniaswithpoorprognosis and a histology clas-
si¢ed as UIP (1). The prognosis of IPF patients has been
correlated to a number of cellular and histological deter-
minants recently and it has been shown that signs of ac-
tive ¢brosis aremost closely correlated to the survival in
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bene¢t in IPF patients (25). Instead, therapy is aimed at
the ¢brotic progresswith agents such as interferon gam-
mawhich for example inhibits signal transducer and acti-
vator of transcription 1 (STAT-1) involved in TGF-b
signaling (26).
In order to test for the anti-¢brotic activity of phar-
macological agentsmarkers have to be de¢ned, that clo-
sely correlatewith the ¢brotic activity andwith relevant
parameters such as the extent of decrease in transfer
factor and total lung capacity (TLC). In this study, we ex-
amined the activity of collagen-metabolism-associated
lysosomal enzyme activities in IPF patients and controls
withoutrestrictive lungdisorders.We foundgood corre-
lation of increased N-ACGA activity with decreased
TLC and decreased transfer coe⁄cient. In addition,
N-ACGA activity was also correlated closely to the con-
centration of TGF-b in the BALF of IPF patients and the
number of eosinophils, neutrophils and activated (but
not total) lymphocytes underscoring its relevance in the
¢brotic process.
Theusefulness of amarker in IPF depends on a number
of factors. Most importantly, a marker has to be vali-
dated in a well-de¢ned disease. Studies using histology
obtained during open lung biopsy are not numerous be-
cause in real life obtaining a valid histological sample re-
sults in considerable mortality especially in elderly UIP
patients (1,27). Criteria have, therefore, been de¢ned
for diagnosis ofUIPon the grounds of clinical andradiolo-
gical evaluation (1). Histology, however, will remain the
gold standard for diagnosing UIP de¢ning IPF.Therefore,
although our study does not encomprise a large number
of patients, those that have been included to exhibit the
characteristics of UIP according to the most stringent
criteria. Our population of patients may appear to be
somewhat younger, suggestive of more number of fe-
males (28) but this may be an e¡ect of our requirement
for surgical lung biopsy. The rate of open lung biopsy in
elderly patients with typical clinical and radiological signs
is low inmanycenters following the recommendations of
the joint ATS and ERS statement (1).
N-ACGA and b-gal aremarkers for increased collagen
metabolism activity cleaving sugar residues from pro-
collagens in collagen synthesis. In addition, both enzymes
can be activated in an initial step of cleaving sugar resi-
dues form collagen molecule.The cleavage of sugar resi-
dues is prior to the rate-limiting step of collagen
degradation catalyzed by collagenase. The increased ac-
tivity of both enzymes suggests an elevated collagen
turnover as well as collagen accumulation. Judging by
the histology of UIP increased collagen turnover appears
to be very plausible concept with ¢broblast foci repre-
senting areas of a highly active ¢brotic process in com-
parison to areas where the damage has already been
done such as honeycomb areas.These later areas do not
exhibit extensive collagen deposits which suggests, thatremoval or degradation is indeed part of the ¢brosing
process. It has been suggested that both increased pro-
duction andreduced collagen degradation are involved in
net collagen deposition (29) since the rate-limiting en-
zyme in degradation is collagenase, and activity that has
been shown to reduce IPF and thus the increased activ-
ities of b-gal and N-ACGA may preferentially lead to
synthesis.The extent of increase in enzyme activity was
di¡erent for N-ACGA and b-gal: While the mean in-
crease in b-gal activity was twofold, the mean increase
in N-ACGA activity was 3.7-fold. It, therefore, appears
that N-ACGA may possess greater usefulness as a mar-
ker enzyme in IPF compared to b-gal.
The increased activity of both enzymes in BALF in IPF
patients together with the ¢nding of unaltered levels in
serum suggest that BALF ¢ndings indicate a process re-
stricted to the pulmonary compartment and therefore
argues for good speci¢city of these markers in terms of
the localization of the ¢brotic process.
Elevated numbers of neutrophils (45%) are thought
to be an indicator of shortened survival (30). It has be-
come more evident in recent years, that survival is not
so much linked to the process described as alveolitis
(i.e. increased alveolar cellularity with lymphocytosis
and increased number of neutrophils and eosinophils)
but is more closely associated with dynamic changes in
¢brotic activity represented, e.g. by ¢broblast foci or
other ‘‘young’’ ¢brotic tissue (28).Thus, it does not come
by surprise to ¢nd a correlation of the relative number of
neutrophils and the activity ofN-ACGA (relative and ab-
solute numbers in BALF) and b-gal (absolute number in
BALF). Neutrophil in£ux and activation may be both a
cause and a consequence of the chronic in£ammatory
process in the lung of IPF patients through their pattern
of early response chemokines and due to their recruit-
ment following increased endothelial adhesion molecule
expression and chemokines gradients. Apart from
chemokines and oxygen radicals that neutrophils may
release in in£ammation, neutrophil elastase may also
possess a role in IPF as neutrophil elastase-de¢cient
mice are more resistant to bleomycin-induced
¢brosis (31).
The correlation of ¢brotic activity (i.e increased
N-ACGA and b-gal activity) and eosinophil number in
BALF is evenmore likely to be an indicator of the predo-
minant Th2 pattern suggested to maintain TGF-b pro-
duction and to promote pulmonary ¢brosis (32). This is
supported by the strong correlation of TGF-b (in BALF)
andN-ACGA activity.
In conclusion, we found elevated activities of both en-
zymes in BALF of patients with IPF, N-ACGA activity
was elevated to a greater extent than b-gal activity.
N-ACGA activity appears to be related to the degree of
¢brotic activity in IPF and may, therefore, be a useful
marker formonitoring the progress as well as therapeu-
tic interventions in IPF.
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